Germany's Siemens to set out plan for $41 billion Healthineers stake

German engineering group Siemens is set to unveil plans to significantly reduce its nearly 70% stake in Siemens Healthineers, a move valued at approximately 35 billion euros and largely driven by major shareholders. This strategic divestment is expected to provide CEO Roland Busch with substantial financial firepower for M&A, allowing Siemens to sharpen its focus on high-growth areas such as artificial intelligence and industrial software. While the method of reduction (e.g., dividend in kind, spin-off, or gradual sell-down) presents complexities and potential tax implications, the shift aims to enhance Siemens' core business and could remove a key overhang for Healthineers' stock.

Analysis

German engineering group Siemens is poised to announce a significant reduction of its nearly 70% stake in Siemens Healthineers, valued at 35 billion euros, driven by major shareholder pressure. This strategic move aims to provide CEO Roland Busch with substantial M&A firepower, enabling Siemens to intensify its focus on high-growth areas like artificial intelligence and industrial software. The divestment is also intended to strengthen Siemens' core business and potentially mitigate takeover rumors.

Siemens shares have outperformed, gaining 31% in 2025 against the Stoxx Europe Industrial Goods & Services index's 21%, while Healthineers' stock has declined 15% due to uncertainty surrounding Siemens' holding. Major shareholders, including Deka Investment, advocate for reducing the stake to 51% or even below 50% to unlock value and strategic clarity.

Barclays identifies three potential methods for the divestment: a dividend in kind, a spin-off, or a gradual sell-down. Each option presents complexities, such as a potential 7 billion euro German tax liability for a dividend in kind, or the risk of share price dilution during a lengthy sell-down process. The chosen method will significantly impact capital allocation and the immediate financial benefits for Siemens.

Key Decisions for Investors

• Investors in Siemens should closely monitor the specifics of the announced Healthineers stake reduction, particularly the chosen method and its implications for M&A capacity and capital returns.
• Healthineers investors should anticipate potential removal of the overhang from Siemens' large stake, which could lead to improved stock performance, but also consider the impact of a potential secondary listing or large share distribution.
• Evaluate Siemens' future M&A targets and strategic shifts into AI and industrial software, as these will be critical drivers for long-term value creation following the divestment.